Posts by Mourabit Halima

The 2025 Beijing Breast Cancer Forum and Breast Reconstruction Symposium, held from June 25 to June 28 in Beijing, was hosted by the Beijing Society for Breast Disease Prevention and Treatment and co-organized by the Breast Center of Peking University People’s Hospital and the Jiaqing Breast Cancer Prevention Foundation. During the conference, Oncology Frontier invited Prof. Que Zhang, Vice President of the Beijing Society for Breast Disease Prevention and Treatment, to provide in-depth insights into the current challenges and future directions of early breast cancer screening in primary care institutions in China. He also reflected on the broader significance of the newly launched “Peking University People’s Hospital Jiaqing Foundation Centennial Legacy Training Program.”

There is currently no universally accepted standard treatment for patients who progress after receiving CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i + ET). In the era of precision medicine, both domestic and international guidelines increasingly recommend biomarker-driven treatment strategies. However, the population covered by each biomarker is often limited, creating an urgent clinical need for more potent and broadly applicable therapies that can simplify both diagnostic testing and treatment selection.

The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation titled “Treatment Challenges of Breast Cancer Liver Metastases in 2025.” In an exclusive interview with Oncology Frontier, Prof. Li elaborated on YBCSG’s major achievements in the first half of 2025 and highlighted key challenges in managing liver metastases in breast cancer.

At the recent "Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association," Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier invited Prof. Wang for an exclusive interview to share insights on the key findings presented at the ASCO 2025 conference in the field of HER2-positive breast cancer and their clinical implications, along with perspectives on future research directions.

Editor’s Note: The DESTINY-Breast09 (DB-09) study, recently presented at the ASCO Annual Meeting, has sparked widespread attention among oncology experts and is poised to reshape the first-line treatment landscape for…

Hubei Association of Radiation Oncology Physicians 2025 Academic Conference Editor’s Note: The 2025 Annual Academic Conference of the Radiation Oncology Physicians Branch of the Hubei Medical Association was recently held…